|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
Business Wire
May 3
Comment
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2012. Targacept reported net income of $2.3 million for the
StreetInsider.com
Apr 30
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AstraZeneca+%28AZN%29+Ends+Pact+with+Targacept+%28TRGT%29+for+TC-5214/7383097.html for the full story.
FierceBiotech
Apr 25
Comment
The late-stage collapse of Targacept's depression drug--TC-5214--will cost the jobs of close to half of the biotech's staffers, with 65 workers getting pink slips today. The news comes a month after Winston-Salem, NC-based Targacept ($TRGT) and...
Business Wire
Apr 25
Comment
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced a reduction in force as part of a strategic plan to focus the company’s resources on its clinical programs and select
Business Wire
Apr 24
Comment
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it will report financial results for the first quarter of 2012 on Thursday, May 3, 2012, after the U.S. financial
StreetInsider.com
Apr 18
Comment
The following is a list of notable articles to help get you through the lunch hour:
Deutsche Bank Maintains a 'Buy' on Intel (INTC); Raising Stakes at 22nm -> Read this!
Shares of Wynn Resorts (WYNN) Up Almost 6% on Jornal Tribuna de Macau...
StreetInsider.com
Apr 18
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Targacept+%28TRGT%29+Can+Fail+and+Yet+Still+Win+for+Investors+-+Barron%27s/7354068.html for the full story.
ValueWalk.com
Apr 16
Comment
Several major investors made moves in the pharmaceuticals arena last week as the ups and downs in that industry came to the fore. The Baupost Group sold off its entire holdings of the Biotechnology firm Targacept Inc. (NASDAQ:TRGT) and SAC...
Business Wire
Apr 10
Comment
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. Following identification of an
market folly
Apr 9
Comment
Seth Klarman
's hedge fund firm
Baupost Group
just now filed an amended 13G with the SEC. In it, they disclose that they've sold completely out of their equity position and no longer own any shares.
This disclosure was made due to activity on...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
